WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?
In this article by Sarah Speight, Sheena Linehan has been quoted alongside the director of IP at the World Trade Organisation and the global patent head of an international law firm.
Potter Clarkson ranked in MIP's IP STARS 2022
Potter Clarkson has secured prominent placing in the 2022 edition of Managing Intellectual Property’s IP STARS - the leading resource for companies or individuals looking for intellectual property firms and practitioners from around the world.
Potter Clarkson achieves top four ranking in Financial Times’ Europe’s Leading Patent Law Firms report 2022
Potter Clarkson has maintained its position as one of the top four patent specialists in Europe, according to the latest Europe’s Leading Patent Law Firms report from the Financial Times.
White paper: Open source, software patents or a combination?
The debate of whether patenting or open source best suits a software developer’s needs still rages. In this white paper we look at both sides of the argument in detail.
LATEST INSIGHTS
Exclusivity, patent licensing and the UPC
Dave Holt, senior associate and licensing specialist, comments on the recent Court of Appeal decision Neurim v Generics [2022] EWCA Civ 359 and its implications on licensing Unitary Patents.
Can patent term extensions pull pharma companies back from the edge of the ‘patent cliff’?
According to many, the anticipated arrival of Humira biosimilars in the US next year has pushed AbbVie's drug to the precipice of the pharma industry’s biggest-ever patent cliff.
Are you ready for the ‘big bang’?
Patent Offices around the world are busy preparing for the ‘big bang’ date of 1 July 2022 on which the new international standard for providing sequence listings (Standard ST.26) will come into force, simultaneously replacing existing Standard ST.25. Applicants and their representatives will need to be aware of the change and its consequences to avoid difficulties.
Aarhus Investor Summit
Aarhus Investor Summit | Science Edition is taking place at INCUBA Navitas in central Aarhus on 18 May 2022. This event connects investors with early stage spinouts and researchers looking to commercialize research-based inventions and solutions.
LSX World Congress
LSX World Congress is taking place in London, UK on 10-11 May 2022. This event gathers the founders and CEOs of innovative biotech, medtech and healthtech start-ups through to healthcare giants, and everyone in between.
Why the devil is in the detail in patent applications
A recent case involving Bristol Myers Squibb, which resulted in the revocation of a patent filed by the pharmaceutical giant, serves as a salutary warning on the risks of failing to include detailed supporting data when an application is first filed.
Probiota 2022
Two of our IP specialists in probiotics and microbiology will be attending this year’s Probiota event in Copenhagen, Denmark, to learn from and network with delegates in academia and industry.
Another active ingredient. Another reference to the CJEU.
The Court of Justice of the EU (CJEU) has once again been asked to explain the eligibility criteria for SPCs for “combination products” - those comprising two or more active ingredients.
EC call for evidence on unitary SPCs
The European Commission has opened a call for evidence on proposals for a single procedure for the granting of SPCs across the European Union.
Will AI accelerate the development of 2D materials?
The Henry Royce Institute and the World Economic Forum have drawn attention to the need for us to accelerate the development of advanced materials, including 2D materials.
European Commission proposes a unified SPC system
The European Commission has announced a new initiative for a single procedure for the granting of SPCs across the European Union.